Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3924 - Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer


09 Oct 2016


Poster display


Grace Gard


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


G. Gard1, T. Van Hagen2, M. Ariyapperuma3, K. Feeney4, R. Roberts-Thomson5, M. Millward6, M. Khattak7

Author affiliations

  • 1 Medical Oncology, Fiona Stanley Hospital, 610 - Perth/AU
  • 2 Medical Oncology, St John of God Hospital, 6150 - Perth/AU
  • 3 Medical Oncology, Sir Charles Gairdner Hospital, Perth/AU
  • 4 Medical Oncology, Notre Dame University, Perth/AU
  • 5 Medical Oncology, The Queen Elizabeth Hospital, Adelaide/AU
  • 6 Medical Oncology, Sir Charles Gairdner Hospital, University Western Australia, Perth/AU
  • 7 Medical Oncology, Fiona Stanley Hospital, University Western Australia, Perth/AU


Abstract 3924


Immune check-point inhibitors (ICI) have revolutionised the treatment of advanced cancer. However, ICI treatment is associated with immune related adverse events (irAEs) leading to patient morbidity and mortality. Safety and efficacy of ICI is not well known in patients with auto-immune (AI) conditions as historically this group has been excluded from clinical trials. The aim of our study was to evaluate the safety and efficacy of primarily anti-PD1 therapy in patients with known AI conditions.


This was a retrospective analysis of patients with advanced cancer treated with ICI at 5 Australian hospitals.


17 patients were identified: melanoma (11), NSCLC (5) and 1 with mRCC. AI conditions: Crohn's disease (1), Ulcerative colitis (3), rheumatoid arthritis (5 including 1 with common variable immune-deficiency), psoriasis (4) and 4 patients with other AI disease. Treatment received: Nivolumab (7 including 1 with prior Ipilimumab), Pembrolizumab (8) and Ipilimumab (2). 11 patients previously received systemic therapy for their AI condition, 2 had topical therapy and 4 had no previous therapy. Two patients had symptoms of active AI disease at time of starting ICI. Disease flared in 6/17 (35%): 3 with G2 arthritis (2 treated with moderate dose steroids, one with anti-inflammatories), G3 colitis treated with high dose steroids, G3 dyspnoea treated with high dose steroids and G2 psoriatic rash treated with low dose steroids. Nil required steroid sparing agents. irAEs unrelated to AI disease flare: 3 patients with pneumonitis, two G2, one G3 all requiring high dose steroids and one patient with G3 colitis requiring high dose steroids. Response rates: complete (1), partial (7), stable (2) progressive disease (5), non-evaluable (2).


Disease flared in 35% of patients with AI conditions undergoing treatment with ICI. Most patients were successfully managed with steroids and treatment was permanently discontinued in only one patient. Although use of ICI in patients with AI conditions seems generally manageable, our data should be interpreted with caution as many patients with AI conditions had no symptoms of active disease at the start of therapy. Response to ICI is similar to historical controls.

Clinical trial identification

Legal entity responsible for the study

G Gard and M Khattak.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings